2 results about "Infectious gastroenteritis" patented technology

The application provides a pig getah virus positive serum and a preparation method and application, and belongs to the technical field of animal virology. The application provides a preparation method of a pig getah virus positive serum, wherein a CDCD pig is used as a host, neutralizing antibody titer obtained through multiple immunization of high-concentration antigen is greater than or equal to 1:512; the serum does not have cytotoxicity affecting cell culture; the CDCD pig is a pig free from maternal antibody interference, which is obtained through caesarean section, isolated feeding and artificial feeding; the positive serum does not detect pig pseudorabies virus, swine fever virus, porcine circovirus type 2, pig foot-and-mouth disease virus, bovine viral diarrhea virus, porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, porcine rotavirus, porcine parvovirus, porcine Japanese encephalitis virus antibody, and has the characteristics of high titer and no cytotoxicity.

This invention belongs to the field of veterinary biological agent technology, specifically relating to a bacterial-enzyme complex preparation for the prevention and treatment of transmissible gastroenteritis (TGEV) in pigs, its preparation method, and its application. The bacterial-enzyme complex preparation comprises microcapsule particles; the core material of each microcapsule particle includes a complex of probiotics and a synergistic enzyme system; the complex of probiotics includes *Lactobacillus rhamnosus*, *Bacillus coagulans*, *Pediococcus pentosus*, and *Kluyveromyces marsupialis*. In the bacterial-enzyme complex preparation for the prevention and treatment of TGEV provided by this invention, the complex probiotics and the synergistic enzyme system form a synergistic effect. Lactic acid secreted by *Lactobacillus rhamnosus* can lower the intestinal pH, disrupting the TGEV survival environment; antimicrobial peptides produced by *Bacillus coagulans* can directly cleave the viral capsid protein; lysozyme can degrade viral envelope polysaccharides; and neutral protease, β-glucanase, and xylanase can destroy the viral adsorption sites on the intestinal mucosa. This quadruple action significantly enhances the antiviral effect.